Literature DB >> 2859185

Antihypertensive effect of felodipine combined with beta-blockade. A comparison between 2 and 3 daily dosages.

B G Hansson, G Lyngstam, O Lyngstam, L Rydén, U Thilén.   

Abstract

24 hypertensive patients, who were not satisfactorily controlled (diastolic blood pressure greater than 95 mm Hg) with beta-blockers alone were randomised to 2 treatment groups where felodipine was administered for 2 weeks in a total daily dose of 15 mg divided in 2 or 3 doses. Following a 2-week placebo washout period, the patients were switched to the alternative dose regimen in a double-blind crossover manner. Blood pressure was measured with standard techniques and was also non-invasively monitored for 24 hours at the end of each dose regimen period and at the end of the intermediate placebo period. Mean arterial blood pressure at the end of the placebo run-in period was 169/105 mm Hg. Felodipine 5 mg thrice daily reduced blood pressure by 20/9 mm Hg and felodipine 7.5 mg twice daily by 17/9 mm Hg (p less than 0.05). The difference between the 2 dose regimens was not statistically significant. When 24-hour blood pressure measurements for the 2 dose regimens were compared, there were no statistically significant differences. Both regimens reduced the 24-hour blood pressure significantly compared with placebo. Two patients were withdrawn during the study, 1 before felodipine treatment started and the other due to diarrhoea and flushing related to felodipine. Otherwise felodipine was generally well tolerated.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2859185     DOI: 10.2165/00003495-198500292-00023

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  7 in total

1.  The treatment of hypertension with verapamil.

Authors:  G R Lewis; K D Morley; B M Lewis; P J Bones
Journal:  N Z Med J       Date:  1978-05-24

Review 2.  Haemodynamics in essential hypertension.

Authors:  P Lund-Johansen
Journal:  Clin Sci (Lond)       Date:  1980-12       Impact factor: 6.124

3.  Drugs and the heart. III. Calcium antagonists.

Authors:  L H Opie
Journal:  Lancet       Date:  1980-04-12       Impact factor: 79.321

4.  Determination of felodipine in plasma by capillary gas chromatography with electron capture detection.

Authors:  M Ahnoff
Journal:  J Pharm Biomed Anal       Date:  1984       Impact factor: 3.935

5.  Treatment of hypertension with nifedipine, a calcium antagonistic agent.

Authors:  M T Olivari; C Bartorelli; A Polese; C Fiorentini; P Moruzzi; M D Guazzi
Journal:  Circulation       Date:  1979-05       Impact factor: 29.690

6.  Felodipine--a new vasodilator, in addition to beta-receptor blockade in hypertension.

Authors:  D Elmfeldt; T Hedner
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  Vasodilating drugs: contrasting haemodynamic effects.

Authors:  R C Tarazi; H P Dustan; E L Bravo; A P Niarchos
Journal:  Clin Sci Mol Med Suppl       Date:  1976-12
  7 in total
  10 in total

Review 1.  Calcium channel antagonism and beta blockade in combination--a therapeutic alternative in cardiovascular disorders. A review.

Authors:  J N Lessem; B N Singh
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

Review 2.  Calcium channel antagonists: Part VI: Clinical pharmacokinetics of first and second-generation agents.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1989-08       Impact factor: 3.727

3.  Treatment of essential hypertension with felodipine in combination with a diuretic.

Authors:  T Hedner; O Samuelsson; E Sjögren; D Elmfeldt
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 4.  Felodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  E Saltiel; A G Ellrodt; J P Monk; M S Langley
Journal:  Drugs       Date:  1988-10       Impact factor: 9.546

5.  Pharmacokinetic interactions between felodipine and metoprolol.

Authors:  S R Smith; M R Wilkins; D B Jack; M J Kendall; S Laugher
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 6.  'Second generation' dihydropyridine calcium antagonists. Greater vascular selectivity and some unique applications.

Authors:  D D Freedman; D D Waters
Journal:  Drugs       Date:  1987-11       Impact factor: 9.546

7.  Verapamil 240 SR versus verapamil 120 SR in arterial hypertension. A randomized double-blind, placebo-controlled study with 24-hour ambulatory blood pressure monitoring.

Authors:  L Corea; M Bentivoglio; S Berioli; C Bianchini; K Savino; M Sardina
Journal:  Cardiovasc Drugs Ther       Date:  1990-12       Impact factor: 3.727

8.  Haemodynamic effects and pharmacokinetics of felodipine at rest and during exercise in hypertensive patients treated with metoprolol or atenolol.

Authors:  B Bengtsson-Hasselgren; D Elmfeldt; L Moberg; O Rönn
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 9.  Calcium channel antagonists. Part V: Second-generation agents.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-07       Impact factor: 3.727

10.  Felodipine in hypertensive patients. A dose finding study in patients refractory to beta-blocker monotherapy.

Authors:  H E Sluiter
Journal:  Drugs       Date:  1987       Impact factor: 9.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.